- BNF:
- Not listed
- Status:
- Red
- Decision Date:
- January 2016
Comments
RED1,2,3,4: NICE TA370: Panobinosat in combination with Bortezomib and dexamethasone for treating multiple myeloma after at least 2 previous treatments.
NHS England drug. To be used in line with NHS England commissioning intentions
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
- 4: Specifically designated as “hospital only” by product licence or by DH/NICE
search again